EU Delays Approval of Novavax's Revised COVID Vaccine
European Union regulators have delayed the decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the Financial Times said on Sunday.The European Medicines Agency , which was due to approve the updated vaccine last Friday has requested more information from the company, the FT report added."As part of the ongoing review process, [the EMA] has additional questions, which we are answering expeditiously," Novavax told the Financial Times.